The definitive agreement is a positive strategic step but provides no near-term revenue or earnings catalyst. Traders should monitor site selection, lease execution, and regulatory milestones over the next 6 months; the first meaningful financial impact is not expected until Q1 2027 at the earliest. The stock's micro-cap status and pre-revenue nature of this expansion mean execution risk is high.
Price Chart
Executive Summary
Vivos Therapeutics announced definitive agreements with South Palm Cardiovascular Associates to form AIM Florida, a physician-aligned management services organization, and establish a regional Sleep & Airway Medicine Center in Palm Beach County. Vivos expects to hold a 75% majority interest, with the center targeting first patient treatments and revenue generation in Q1 2027 and an initial team capable of generating up to $6 million in annual revenue at 30%+ contribution margins. This is a strategic expansion of Vivos' SAMC model into a new market with a large cardiology referral base, but the center is pre-revenue with significant execution risk and no near-term financial impact.
Key Facts
- Vivos executed definitive collaboration and operating agreements with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, a physician-aligned management services organization.
- Vivos expects to hold a 75% majority of the membership and economic interests in AIM Florida.
- The planned Sleep & Airway Medicine Center in Palm Beach County is expected to begin treating patients and generating revenue in the first quarter of 2027.
- The initial fully staffed Sleep Optimization Team is expected to serve approximately 250 patients per month and generate up to $6 million in annual revenue with contribution margins of 30% or more.
- SPCVA is a multi-location, physician-owned cardiology practice with approximately 30,000 patients of record.
- The center will integrate sleep testing, medical evaluation, and treatment options including PAP therapy, FDA-cleared oral appliances, laser therapy, and myofunctional therapy.
- Vivos CARE appliances are the only oral medical devices FDA-cleared to treat moderate to severe OSA in adults and children ages 6-17.
Financial Impact
Pre-revenue; initial team expected to generate up to $6M annual revenue at 30%+ contribution margins once fully deployed, but no revenue or profit contribution until at least Q1 2027.
Risk Factors
- Execution risk: site selection, lease, build-out, licensing, payer enrollment, and staffing may delay or prevent the center's opening.
- Capital requirements: startup costs may exceed expectations, and Vivos may need additional financing.
- Patient demand and reimbursement may not materialize as anticipated.
- Regulatory and compliance risks associated with management services and clinical arrangements.
- Vivos may be unable to maintain its Nasdaq listing or access additional financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352691 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1340 (−0.52%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1340 (−4.96%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1340 (−4.69%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1340 (−6.16%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1340 (−6.16%) |
Sep 30, 2026 25d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1340 (+10.07%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1340 (−40.42%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1340 (−51.59%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1340 (+55.51%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1340 (−60.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers